Market Outlook:

NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2017-2027 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. EGFR and ALK inhibitors will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively.

Questions Answered:

How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time?

What is the current state of treatment in NSCLC? What are interviewed experts’ insights on current treatment options?

What clinical needs remain unfulfilled? What pipeline products are most promising, and what sales/uptake could they secure in NSCLC?

What therapies of note are progressing in earlier phases? What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

 


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details

Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i...

View Details